AxoSim, Inc. acquired the microBrain™-associated assets of Vyant Bio’s StemoniX subsidiary in October 2023. The microBrain™ technology provides a physiologically relevant human iPSC-derived screening platform for CNS drug discovery and toxicity testing. The organoid platform replicates important human CNS biology, containing cortical neurons and astrocytes that self-organize and form functional networks in 3D. The hallmark of the microBrain™ organoids is their remarkably consistent performance, making them ideal for high-throughput neurotoxicology, neuromodulation, and drug discovery investigations. For more information about microBrain™ contact sales@axosim.com